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Non-Hodgkin lymphoma (NHL) constitutes a collection of lymphoproliferative disorders with widely varying
biological, histological, and clinical features. For the B cell NHLs, great progress has been made due to the
addition of monoclonal antibodies and, more recently, other novel agents including B cell receptor signaling
inhibitors, immunomodulatory agents, and proteasome inhibitors. Autologous hematopoietic cell trans-
plantation (auto-HCT) offers the promise of cure or prolonged remission in some NHL patients. For some
patients, however, auto-HCT may never be a viable option, whereas in others, the disease may progress
despite auto-HCT. In those settings, allogeneic HCT (allo-HCT) offers the potential for cure. Over the past 10 to
15 years, considerable progress has been made in the implementation of allo-HCT, such that this approach
now is a highly effective therapy for patients up to (and even beyond) age 75 years. Recent advances in
conventional lymphoma therapy, peritransplantation supportive care, patient selection, and donor selection
(including the use of alternative hematopoietic cell donors), has allowed broader application of allo-HCT to
patients with NHL. As a result, an ever-increasing number of NHL patients over age 60 to 65 years stand to
beneﬁt from allo-HCT. In this review, we present data in support of the use of allo-HCT for patients with
diffuse large B cell lymphoma, follicular lymphoma, and mantle cell lymphoma. These histologies account for
a large majority of allo-HCTs performed for patients over age 60 in the United States. Where possible, we
highlight available data in older patients. This body of literature strongly supports the concept that allo-HCT
should be offered to ﬁt patients well beyond age 65 and, accordingly, that this treatment should be covered by
their insurance carriers.
 2016 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).dgments on page 1549.
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In many cases of high-risk non-Hodgkin lymphoma
(NHL), the sole potentially curative option for patients
(regardless of age) remains allogeneic hematopoietic
cell transplantation (allo-HCT). With recent advances
in pretransplantation, peritransplantation, and post-
transplantation care, allo-HCT can now be successfullyshed by Elsevier Inc. This is an open access article under the CC BY-NC-ND
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with advanced age. Although it is true that advanced age
does increase the risk of transplantation-related complica-
tions and nonrelapse mortality (NRM), allo-HCT still often
represents the sole realistic option for cure in many older
patients. After careful consideration of risks, beneﬁts, and
alternatives, an increasing number of patients into their 70s
are electing to undergo allo-HCT.
In this report, we begin by reviewing 3 B cell NHL sub-
types: diffuse large B cell lymphoma (DLBCL), follicular
lymphoma (FL), and mantle cell lymphoma (MCL). These 3
lymphoma histologies accounted for 73% of allo-HCTs per-
formed in patients over age 60 in the United States between
2010 and 2014 (Personal communication, Mehdi Hamadani,
Center for International Blood and Marrow Transplant
Research, April 18, 2016). For each subtype, we ﬁrst provide a
brief overview of the use of nontransplantation frontline
therapies. We next brieﬂy review outcomes for autologous
hematopoietic cell transplantation (auto-HCT), and discuss
the available data supporting the use of allo-HCT. Finally, we
present data speciﬁcally supporting allo-HCT in elderly pa-
tients with lymphoma.DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
Overview of DLBCL and Nontransplant treatment
Options
The most common type of aggressive NHL, DLBCL
encompasses several clinical-pathological entities. Although
risk factors include HIV infection, solid organ trans-
plantation, and autoimmune disorders, most cases are spo-
radic and occur predominantly in individuals age >60 years
with no obvious predisposing factors. Overall, 60% of those
affected will be cured with chemoimmunotherapy. Clinical
factors such as the National Comprehensive Cancer Network
(NCCN) International Prognostic Index (NCCN-IPI), however,
delineate a wide range of results, identifying groups with a
likelihood of 5-year survival ranging from as high as 96% to as
low as 38% [1,2]. A greater understanding of biology and
genetics has reﬁned prognostic markers with potential
therapeutic implications, such as the putative cell of origin
(deﬁned by gene expression proﬁle or immunohistochem-
istry) [3,4], and translocation or overexpression of the MYC
oncogene [5].
Despite these advances, several disease subsets repre-
sent high-risk disease, clinically deﬁned by the NCCN-IPITable 1
Recent Studies Reporting Outcomes of Allo-HCT for DLBCL (>40 Patients)
Study No. of
Patients
Previous
Auto-HCT, %
Conditioning (%)
Thomson et al., 2009 [12] 48 69 RIC (100)
Sirvent et al., 2010 [13] 68 79 RIC (100)
Lazarus et al., 2010 [14] 79* 0 MAC (100)
van Kampen et al., 2011 [15] 101 100 MAC (37)
RIC (63)
Rigacci et al., 2012 [16] 165 100 MAC (30)
RIC (70)
Bacher et al., 2012 [17] 396 32 MAC (42)
RIC (58)
Hamadani et al., 2013 [18] 533y 25 MAC (58)
RIC (42)
Fenske et al., 2015 [19] 503 100 MAC (25)
RIC (75)
NR indicates not reported.
* Analysis restricted to patients undergoing MA allo-HCT as ﬁrst transplantation
y Included 85% DLBCL and 15% FL grade 3; all patients had chemoresistant disea[1], or biologically identiﬁed, for example the “double-hit”
and “triple-hit” lymphomas (ie, those with MYC and BCL2
and/or BCL6 translocations). Particularly for double- and
triple-hit lymphomas, standard frontline therapies are
ineffective for providing long-term remission, and cure is
rarely achieved in the relapsed and refractory settings. Thus,
selecting the optimal therapy for such patients remains a
great challenge [5,6].
Auto-HCT for DLBCL
High-dose chemotherapy with auto-HCT exploits the
steep dose-response curve of some chemotherapy agents, by
eradicating disease that could not be eliminated by con-
ventional chemotherapy doses. Two decades ago, a ran-
domized trial conducted in patients with relapsed aggressive
lymphoma with chemosensitive disease showed a 53% 5-
year survival with auto-HCT versus 32% with continuation
of conventional chemotherapy [7]. Even in the rituximab era,
some patients with disease relapse will be long-term survi-
vors after proper second-line therapy and auto-HCT [8];
however, signiﬁcantly worse results are expected in patients
who never achieve complete response (CR) with frontline
therapy, who have a short duration of CR, or relapse with a
high IPI. For example, in the CORAL trial, fewer than 25% of
patients who relapsed within 1 year of diagnosis achieved
long-term disease-free survival with auto-HCT [9].
Investigations of strategies designed to improve on auto-
HCT, such as modifying the transplant preparative regimen
with the addition of radioimmunotherapy to the chemo-
therapy backbone [10] or the use of post-transplantation
maintenance therapy [11], have not proven beneﬁcial in
relapsed/refractory (R/R) DLBCL. Auto-HCT remains the
standard of care for chemosensitive R/R DLBCL, but better
approaches are needed for patients who experience relapse
after auto-HCT or for whom auto-HCT is not an option due to
insufﬁcient chemosensitivitity.
Allo-HCT for DLBCL
Recent studies of allo-HCT involving at least 40 patients
with DLBCL are listed in Table 1. Allo-HCT provides the
theoretical advantage of a tumor-free graft and the beneﬁt of
a graft-versus-lymphoma (GVL) effect. This GVL effect has
been well demonstrated by the fact that some patients who
experience relapse after auto-HCT will attain cure with allo-
HCT. Furthermore, the use of donor lymphocyte infusion,Median Age,
yr (Range)
NRM/TRM, % (yr) Relapse, % (yr) OS, % (yr)
46 (23-64) 32 (4) 33 (4) 48 (4)
48 (17-66) 23 (1) 41 (2) 49 (2)
46 (21-59) 43 (3) 33 (3) 26 (3)
46 (18-66) 28 (3) 30 (3) 52 (3)
43 (16-65) 19-32 (2) NR 39 (5)
54 (18-66) 36-56 (5) 26-40 (5) 18-26 (5)
46 (19-66)
53 (20-70)
53 (3)
42 (3)
28 (3)
35 (3)
19 (3)
28 (3)
52 (19-72) 31 (5) 40 (5) 34 (5)
.
se pretransplantation.
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provides a GVL effect in DLBCL after allo-HCT, leading to cure
in some cases [12,20,21]. Allo-HCT, however, presents chal-
lenges including donor availability, the need for prolonged
immunosuppression, and an increased risk of early
treatment-related mortality (TRM) owing to toxicity of the
conditioning regimen, graft-versus-host disease (GVHD), and
infectious complications. Progress in addressing these chal-
lenges has been made in recent years.
In the past, allo-HCT used myeloablative conditioning
(MAC) to eliminate maximal tumor and permit engraftment
by eliminating the host immune system. No prospective
trials comparing auto-HCT versus MAC allo-HCT for R/R
DLBCL have been undertaken to date. A large retrospective
analysis by the Center for International Blood and Marrow
Transplant Research (CIBMTR) including 837 auto-HCTs and
79 allo-HCTs performed between 1995 and 2003 demon-
strated higher TRM, NRM, and overall mortality in the
allo-HCT group, with no decrease in the risk of disease pro-
gression [14]; however; the subjects who underwent allo-
HCT were more likely to have high-risk disease features,
including later disease stage, to have received more previous
chemotherapy regimens, and to have resistant disease.
Despite such limitations, reviewing the literature on allo-
HCT reveals a consistent message that long-term overall
survival (OS) in the 20% to 50% range is possible (Table 1). The
25% to 30% rate of NRM remains the greatest drawback. Less-
intensive preparative regimens (termed reduced-intensity
conditioning [RIC]) have been implemented in recent years.
Retrospective comparisons between MAC and RIC show
reduced NRM, at the expense of some increase in disease
relapse, but producing long-term OS rates comparable to
those for MAC [17,18]. Most allo-HCTs for DLBCL are now
performed using lower-intensity regimens, which also per-
mits the use of this procedure in older patients who are
otherwise good candidates but previously would have been
excluded from MAC allo-HCT because of age [17]. The
expanding use of allo-HCT in older patients is evidenced by
the fact that the more recent studies listed in Table 1 include
patients 65 to 72 years of age. One recent study focusing on
the use of allo-HCT in patients with NHL in their 60s and
early 70s found no major increase in NRM for such patients
[22].
Allo-HCT for DLBCL following failed auto-HCT
Roughly 30% to 40% of DLBCL auto-HCT recipients ulti-
mately will experience relapse or progression of DLBCL and
cannot be cured with intensiﬁcation of chemotherapy. As
noted above, because of the GVL effect in DLBCL, such pa-
tients are often considered for allo-HCT after a failed previ-
ous auto-HCT [15,16,19,23]. These studies report TRM/NRM
rates of 17% to 31% but 3- to 5-year OS rates of 34% to 52%. In
the most recent and largest study, from the CIBMTR, 503
patients were analyzed. At 3 years, NRM was 30%, with a
progression/relapse rate of 38% and OS of 37%, a reasonable
result given that the median survival typically seen in this
population is in the 3- to 10-month range [24,25]. In multi-
variate analysis, advanced age was not a prognostic factor,
indicating that chronologic age should not be the key factor
used to determine allo-HCT eligibility. A prognostic model
was constructed using Karnofsky Performance Status <80,
time from auto-HCT to allo-HCT of <1 year, and chemo-
resistant disease as adverse factors. This CIBMTR model fa-
cilitates the identiﬁcation of high-risk patients unlikely to
beneﬁt from allo-HCT (3-year OS of 14%), as well as low-riskpatients who have good potential to beneﬁt from allo-HCT
(3-year OS of 43%) [19].Summary: DLBCL
These data indicate that medically appropriate patients
with DLBCL whose disease relapses after auto-HCT have the
clearest indication for allo-HCT and potentially can be cured.
In this setting, patients should receive RIC preferentially,
ideally after conventional debulking therapy. Other subsets
of patients who may beneﬁt from allo-HCT are patients
known to have a low chance of cure with auto-HCT, as
identiﬁed by use of the second-line IPI, failure to attain CR
using initial therapy, relapse <12 months after chemo-
immunotherapy, or NHL refractory to second- and third-line
chemotherapy [9,18,20,26]. The recently developed CIBMTR
prognostic model described above can guide decision mak-
ing [19]. Other appropriate indications include (1) patients in
whom auto-HCT is not feasible, either by failure to obtain an
adequate autologous graft for transplantation or coexistence
of intrinsic bone marrow disease, particularly myelodys-
plastic syndrome; (2) DLBCL transformed from an indolent
B cell malignancy relapsing after anthracycline-containing
therapy, or a failed auto-HCT; and (3) double-hit DLBCL.FOLLICULAR LYMPHOMA (FL)
Overview of FL and Nontransplant treatment
Options
FL is the most common subtype of indolent NHL, ac-
counting for roughly 20% of all cases of NHL. Unlike patients
with aggressive NHL, nearly all patients who complete in-
duction therapy will eventually relapse and require addi-
tional lines of therapy. Furthermore, although OS is
prolonged for many patients, with standard therapies FL
remains incurable for the vast majority. The Follicular Lym-
phoma International Prognostic Index (FLIPI) incorporates
clinically based features and identiﬁes a subgroup at high
risk for early disease-related death [27]. Approximately one-
quarter of all patients with FL fall into this poor-risk category
(ie,3 risk factors), which has an estimated 5-year OS of only
53%.
A proportion of patients may be safely observed without
treatment until the development of symptomatic progres-
sive disease, bulky adenopathy, cytopenia, organ obstruction,
or malignant ﬂuid collection [28]. Patients who require
therapy but otherwise have a low tumor burden may be
managed with single-agent rituximab [29]; however, many
patients require combination chemoimmunotherapy.
Currently, bendamustine-rituximab may be a preferred
frontline approach in FL with a high tumor burden, with
improved progression-free survival (PFS) (median, not
reached versus 41 months; P ¼ .0072) and decreased toxicity
compared with R-CHOP (rituximab, cyclophosphamide,
doxorubicin, vincristine, and prednisone) [30].
There is no standard therapy for R/R FL; readily available
options include anti-CD20 immunotherapies, combination
chemotherapy, radioimmunotherapy, the oral PI3 kinase
idelalisib, immunomodulatory drugs (lenalidomide), and the
Bruton tyrosine kinase inhibitor ibrutinib [31]. More inten-
sive treatments often are considered for high-risk patients,
especially those who relapse early after induction therapy,
because relapse within 2 years of initial therapy is associated
with a 5-year OS of only 50% [32]. In this context, auto-HCT
and allo-HCT can provide for long-term survival in R/R FL.
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Auto-HCT for FL in ﬁrst remission
The data to support auto-HCT for FL in ﬁrst remission are
limited. Prospective randomized trials comparing chemo-
therapy with auto-HCT in ﬁrst complete remission have
generally shown a PFS beneﬁt, but not an OS beneﬁt, in favor
of up-front auto-HCT [33-36]. Beneﬁt in terms of improved
lymphoma-speciﬁc survival appears to be offset by a
decrease in survival owing to secondary malignancies, such
as myelodysplastic syndrome and acute myelogenous leu-
kemia. As a result, auto-HCT is not recommended for
consolidation of remission after ﬁrst-line therapy for low-
grade FL.
Auto-HCT for R/R FL
Although auto-HCT can produce prolonged remissions, it
typically is not viewed as curative therapy in R/R FL. Pro-
spective studies are lacking, although a randomized study
(n ¼ 89) from the pre-rituximab era, which closed early due
to poor accrual, showed improved 2-year PFS and 4-year OS
in auto-HCT recipients compared with patients receiving
standard chemotherapy [37]. A review of 2 French studies
demonstrated that rituximab at relapse appeared to have a
more prominent impact on event-free survival and OS
compared with receipt of auto-HCT [38]. At least 9 additional
single-center retrospective studies and large registry studies
of R/R FL have demonstrated PFS in the 30% to 60% range at 5
to 10 years, although not all of the patients in these series
were treated with rituximab [39]. Considering that a large
majority of patients with FL relapse after auto-HCT, this
approach cannot be considered a curative intervention for
most patients with FL. However, auto-HCT is a reasonable
consideration and may provide prolonged disease control in
high risk FL patients who are not candidates for allo-HCT.
Allo-HCT for FL
There are no randomized prospective trials or retrospec-
tive studies to support the application of allo-HCT as
consolidation therapy for FL in ﬁrst remission. However,
numerous prospective as well as retrospective studies sup-
port the use of allo-HCT in R/R FL. Outcomes reported by
selected studies investigating allo-HCT in R/R FL are pre-
sented in Table 2.
Allo-HCT for R/R FL: prospective studies
Shea et al. [50] reported a prospective study of 16 patients
receiving RIC allo-HCT conditioned with ﬂudarabine/Table 2
Studies Evaluating Allo-HCT in Relapsed/Refractory FL (>30 Patients)
Study No. of
Patients
Conditioning (%) Age, yr,
Median (Rang
Rezvani et al., 2008 [40] 46 RIC 54 (33-66)
Hari et al., 2008 [41] 208 MAC (58)
RIC (42)
44 (27-70)
51 (27-70)
Piñana et al., 2010 [42] 37 RIC 50 (34-62)
Thomson et al., 2010 [43] 82 RIC 45 (26-65)
Khouri et al., 2012 [44] 47 RIC 53 (33-68)
Evens et al., 2013 [45] 48 NR 50 (27-64)
Robinson et al., 2013 [46] 149 RIC 51 (33-66)
Klyuchnikov et al., 2015 [47] 268 RIC 52 (27-74)
Klyuchnikov et al., 2015 [48] 70 RIC 53 (36-64)
Yano et al., 2015 [49] 46 RIC 48 (34-66)
MRD indicates matched related donor.cyclophosphamide and a matched related donor graft. The 3-
year event-free survival was 75%, and 3-year OS was 81%; 3
subjects relapsed. A second prospective study of 47 patients
conducted at M.D. Anderson Cancer Center used RIC condi-
tioning with ﬂudarabine, cyclophosphamide, and rituximab
[51]. The median 5-year PFS and OS were both 85%; 7 pa-
tients died, most from infectious complications. Another
report combined 2 prospective multicenter Spanish trials in
37 patients who received ﬂudarabine/melphalan RIC
regimen [42]. The relapse incidence was only 8%, but NRM
was as high as 71% in patients with active disease before allo-
HCT. For patients in CR before transplantation, the 4-year OS
was 71%, comparable to those reported in other studies. In a
prospective study from the United Kingdom that enrolled 82
consecutive patients with FL treated with ﬂudarabine,
melphalan, and alemtuzumab RIC, NRMwas 15%, relapse rate
was only 26% at 4 years, and OS was 76% at 4 years [43].
Finally, another prospective multicenter study in 46 patients
with FL coordinated by the Fred Hutchinson Cancer Research
Center [40] reported a high 42% rate of NRM, driven in large
part by the use of mismatched unrelated allografts. The
relapse rate at 3 years was low, at 14%.
Allo-HCT for R/R FL: retrospective studies
The NCCN compared outcomes in 48 allo-HCT and auto-
HCT recipients [45]. The allo-HCT recipients had a 3-year
NRM of 26%; in a multivariable analysis, allo-HCT was
associated with an increased risk of death compared with
auto-HCT (P ¼ .002). These data should be interpreted with
caution, however, as the group of FL allo-HCT recipients
were a highly select and high-risk group. In contrast, a
recent and larger analysis by the CIBMTR indicates that
long-term remission is feasible in a signiﬁcant number of R/
R FL patients who receive allo-HCT, and that patients who
do not die early in the post-transplantation course have
prolonged survival compared with patients receiving auto-
HCT. Among 268 relapsed patients with grade 1 to 2 FL
who underwent RIC allo-HCT, the 5-year NRM was 26%., the
probability of disease progression at 5 years was 20%, and
the 5-year PFS was 41%, representing a subset of patients
who are likely cured of their disease. The 5-year OS was 66%,
and among 24-month survivors, the subsequent risk of
death was decreased in patients undergoing allo-HCT
compared with those undergoing auto-HCT (RR, 2.09;
P ¼ .04) [47]. A recent retrospective study from Memorial
Sloan-Kettering compared outcomes for patients with R/R
FL undergoing auto-HCT versus allo-HCT in the post-e)
TRM/NRM,
% (yr)
Relapse,
% (yr)
OS, % (yr) Comments
42 (3) 14 (3) 52 (3) Prospective
23 (1) 8-17 (3) 62-71 (3) Retrospective (CIBMTR)
37 (4) 8 (4) 57 (4) Prospective
15 (4) 26 (4) 76 (4) Prospective
15 (8) 4 (8) 85 (8) Prospective; 45/47 MRD
24 (3) 16 (3) 61 (3) Retrospective (NCCN)
22 (3) 20 (5) 67 (5) Retrospective (EBMT)
26 (5) 20 (5) 66 (5) Retrospective (CIBMTR);
grade 1 and 2 FL
27 (5) 20 (5) 54 (5) Retrospective (CIBMTR);
grade 3 FL
23 (5) 15 (5) 81 (5) Retrospective (Japan)
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with a remission duration of <12 months before salvage
therapy, 3-year event-free survival was 42% with auto-HCT
versus 80% with allo-HCT, suggesting that patients with a
very short ﬁrst remission (<1 year) may be better served
with an allo-HCT approach [52].
Allo-HCT for grade 3 FL
A recent report from the CIBMTR examined the outcomes
of 61 patients who underwent RIC allo-HCT for grade 3 FL
[48]. At 5 years, NRM was 27% and OS 54%, indicating that
grade 3 histology should not be an exclusion factor for
allo-HCT, and that RIC can offer long-term survival for pa-
tients with grade 3 histology.Summary: FL
Although auto-HCT is not considered a curable interven-
tion for most patients, a subset (w30% to 35%) may enjoy
long-term (>5-year) remissions with this therapy, justifying
its use in second or third remission. Furthermore, given the
development of less-toxic novel therapeutic strategies in the
modern era, the use of auto-HCT may decline in the coming
years. It should be noted that these novel strategies are not
currently known to be curative. In contrast, allo-HCT
repeatedly has been shown to be a curative therapy for a
signiﬁcant subset of patients with R/R FL. Although the rate
of early death is increased in patients with FL receiving allo-
HCT owing to increased NRM, the studies cited above
demonstrate excellent long-term outcomes in those surviv-
ing the early period. With the increasing application of RIC
allo-HCT, and continued improvement in supportive care,
NRM rates likely will continue to decline for well-selected
patients with FL who receive expert supportive care. Such
patients can expect a reasonable chance of being cured.
These observations apply to patients over age 65 years, for
whom outcomes with RIC are comparable to, or only mini-
mally less favorable than, those in the 55- to 64-year age
group [22].MANTLE CELL LYMPHOMA (MCL)
Overview of MCL and Nontransplant treatment
Options
MCL comprises w6% of newly diagnosed cases of NHL.
Themedian age at diagnosis is in the late 60s, with a 4:1male
predominance. Patients often present in an advanced disease
stage, along with extranodal involvement. Modern chemo-
immunotherapies alone, or as induction followed by auto-
HCT in ﬁrst remission, undoubtedly have improved patient
outcomes; however, disease relapse eventually occurs in
most patients [53].
Although variables such as histology (eg, blastoid
morphology), tumor proliferation index, cytogenetics, and
gene expression proﬁling have prognostic value in MCL, their
clinical applications for risk-adapted treatment remains
limited [45]. The MCL International Prognostic Index (MIPI)
is a commonly used risk-stratiﬁcation score based on patient
age, performance status, serum lactate dehydrogenase, and
white blood cell count at diagnosis, with/without Ki-67
proliferation index, that classiﬁes MCL into low-, interme-
diate-, and high-risk groups, with median OS ranging from
29 months to > 5 years [54]. This index also has been vali-
dated to predict outcomes after auto-HCT [55], but has not
yet been validated as a tool to direct optimal consolidation
therapies in patients responding to frontline therapies.Historically, using conventional frontline therapy such as
R-CHOP, the median duration of remission was only 12 to
18 months [56]. Recently, however, incorporation of such
agents as bortezomib, bendamustine, and lenalidomide into
ﬁrst-line therapy have improved on this result, with PFS in
the 27- to 35-month range or longer [30,57-59]. Intensive
regimens like R-Hyper-CVAD (rituximab, fractionated
cyclophosphamide, vincristine, doxorubicin, and dexameth-
asone alternating with methotrexate and cytarabine)
without subsequent consolidation led to impressive PFS in
some reports, but toxicity concerns have dampened enthu-
siasm for this approach [60-62].
Given the relatively short remissions observed in MCL,
investigators have tested the concept of maintenance ritux-
imab after conventional frontline therapies. The median
duration of ﬁrst remission has improved to the 3- to 5-year
range. As a result, rituximab maintenance is a reasonable
option for elderly patients with MCL who are not candidates
for HCT [63,64].
Auto-HCT for MCL
Auto-HCT for MCL in ﬁrst remission
In the pre-rituximab era, the poor prognosis seen in
relapsed MCL motivated the European MCL Network to
conduct a randomized, prospective postremission trial
comparing auto-HCT with IFNa maintenance [65]. Auto-HCT
demonstrated superior PFS; however, no OS beneﬁt was
seen, possibly due to crossing over of the IFNa-treated pa-
tients to subsequently receive auto-HCToff protocol. Although
similar prospective randomized data in the rituximab era are
not available, several large prospective phase 2 trials applying
up-front auto-HCT after various intensive induction regimens
have yielded median PFS durations in the 5- to 7-year range
[66-71]. Despite the lack of randomized, controlled data
demonstrating a survival beneﬁt with auto-HCT as consoli-
dation in ﬁrst remission, many clinicians have adopted this
approach. Certain patients, such as those not in CR at the time
of up-front auto-HCT [72], those with minimal residual dis-
ease pretransplantation [73], or those with a high-risk MIPI
score [55,68,74], fare considerably lesswell with upfront auto-
HCT consolidation, underscoring the need for novel modal-
ities to consolidate ﬁrst remission for such patients.
Auto-HCT for relapsed/refractory MCL
Initial retrospective studies, including a European Society
of Blood and Marrow Transplantation (EBMT) study [75],
have suggested that auto-HCT may have limited value in
relapsed and refractory patients. More recent studies, how-
ever, including a large retrospective study from the CIBMTR,
have indicated that durable remissions in the 2- to 4-year
range may be seen in selected patients with MCL whose
disease remains chemosensitive [72,76]. Therefore, in pa-
tients with relapsed chemosensitive MCL who are not can-
didates for potentially curative allo-HCT (due to
comorbidities, donor availability, etc), consolidation with an
auto-HCT can be offered, with the understanding that this
therapy is not curative. It remains to be seen whether auto-
HCT will remain part of the treatment paradigm for R/R
MCL in the era of new and novel agents.
Allo-HCT for MCL
Allo-HCT for MCL in ﬁrst remission
Although adoptive immunotherapy in the form of allo-
HCT is a potentially curative option for patients with MCL,
there are no prospective data assessing this approach in ﬁrst
Table 3
Studies Evaluating Allo-HCT in Relapsed/Refractory MCL (>30 Patients)
Study No. of
Patients
Conditioning (%) Age, yr,
Median (Range)
TRM/NRM,
% (yr)
Relapse,
% (yr)
OS, % (yr)
Maris et al., 2004 [77] 33 RIC (100) 53 (33-70) 9 (2) 16 (2) 65 (2)
Cook et al., 2010 [78] 70 RIC (100) 52 (25-69) 18 (3) 65 (5) 37 (5)
Le Gouill et al., 2012 [79] 70 RIC (100) 56 (33-67) 32 (2) 18 (2) 53 (2)
Hamadani et al., 2013 [80],* 202 MAC (37)
RIC (63)
54 (27-69)
59 (42-75)
38-43 (1) 32-33 (3) 25-30 (3)
Fenske et al., 2014 [72],y 88 RIC (100) 58 (26-75) 17 (1) 38 (5) 31 (5)
Krüger et al., 2014 [81] 33 MAC (21)
RIC (79)
59 (33-69) 24 (5) 15 (5) 73 (5)
* Included only patients with refractory disease.
y Excluded patients with refractory disease.
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of allo-HCT versus auto-HCT in ﬁrst CR or partial remission
showed no beneﬁt in terms of PFS (55% versus 52% at 5 years)
or OS (62% versus 61% at 5 years); however, early allograft
was associated with a signiﬁcantly higher NRM (25% versus
3% at 1 year) [72]. As a result, the use of allo-HCT in che-
mosensitive patients with MCL in ﬁrst remission generally is
not recommended. Early use of allo-HCTcan be considered in
selected patients for whom the chance for success with auto-
HCT is poor, such as those with high MIPI score or not in CR
before transplantation. It has been hypothesized that in such
patients, outcomes might be improved by early allografting.
This approach would not yet be considered standard care by
most clinicians, but warrants prospective investigation.
Allo-HCT for R/R MCL
As shown in Table 3, evidence from several single-center
studies and large transplantation registries have established
that allo-HCT is the sole potentially curative modality for R/R
MCL, with 35% to 45% of patients disease-free (and likely
cured) at 3 years post-transplantation [72,77-81]. Chemo-
sensitive disease and adequate performance status are pre-
dictive of improved allo-HCT outcomes. In recent years, the
wider adoption of RIC regimens has extended the availability
of allo-HCT to elderly patients and patients with medical
comorbidities. Nonetheless, the prognosis remains particu-
larly poor in the challenging subset of patients with
chemotherapy-unresponsive MCL. A large CIBMTR analysis
restricted to such chemorefractory patients showed that
approximately one-quarter gain durable disease control with
allo-HCT, likely due to a clinically relevant GVL effect [80]. No
beneﬁt of MAC was seen even in this high-risk cohort of
patients. Thus, in otherwise healthy patients with relapsed or
refractory MCL and an available sibling or adult unrelated
donor, RIC allo-HCT with curative intent is a reasonable
therapeutic option. In medically ﬁt patients without signiﬁ-
cant comorbidities, advanced age should not be considered a
contraindication.Figure 1. Increase in proportion of NHL patients over age 60 undergoing allo-
HCT in the United States between 1996 and 2014. Data provided by the Center
for International Blood and Marrow Transplant Research.Summary: MCL
Currently, both auto-HCT and allo-HCT play important
roles in the management of MCL. Auto-HCT is not considered
curative therapy for MCL, although an intensive induction
and consolidation from auto-HCT may provide many pa-
tients with remissions that can last 6 to 8 years or longer.
Selected patients with MCL who did not undergo auto-HCT
as part of frontline therapy also may beneﬁt from auto-HCT
later in the disease course. Despite the recent emergence of
several exciting new agents, for the vast majority of patients
with R/R MCL, allo-HCT remains the sole treatment optionwith curative potential. With the widespread implementa-
tion of RIC, properly selected patients with MCL who receive
expert supportive care have a reasonable chance of being
curedwith allo-HCT. This also applies to patients over age 65,
in whom outcomes with RIC are comparable to those in the
55- to 64-year age group [22].
ALLO-HCT IN OLDER PATIENTS WITH LYMPHOMA
Tables 1-3 list numerous key studies of allo-HCT in DLBCL,
FL, andMCL, several of which include patients up to age 70 to
75 years. A recent registry study by McClune et al. [22]
speciﬁcally analyzed outcomes in 82 patients age 65 un-
dergoing allo-HCT for NHL. Although 100-day NRM was not
signiﬁcantly different, NRM at 1 year was higher in this older
age group (34%) compared with 2 younger populations, 40 to
54 years (27%) and 55 to 64 years (22%). Relapse rates at
3 years were similar across the 3 age groups (28% to 33%). Not
surprisingly, OS was highest in the 40- to 54-year age group;
however, the65-year age group fared reasonably well, with
a 3-year OS of 39%. Nonetheless, it should be emphasized
that in individual patients over age 65, the real question
should be not whether allo-HCT outcomes are comparable to
those in patients under age 65, but rather whether allo-HCT
offers the best reasonable chance for long-term remission or
cure for that patient, when considering all treatment options.
Owing in part to the advances in patient selection, donor
selection, pretransplantation lymphoma therapy, and peri-
transplantation supportive care, older patients are increas-
ingly undergoing allo-HCT. As shown in Figure 1, data from
the CIBMTR show increasing use over time of allo-HCT for
NHL in patients age >60 years. For example, the percentage
of patients age >60 undergoing allo-HCT for DLBCL, FL, and
T.S. Fenske et al. / Biol Blood Marrow Transplant 22 (2016) 1543e1551 1549MCL rose from 12%, 10%, and 23%, respectively, in 2001 to
2005 to 31%, 28%, and 48%, respectively in 2011 to 2014
(personal communication, CIBMTR). These ﬁgures clearly
show that allo-HCT is an important therapeutic option for
DLBCL, FL and MCL, even in older patients. In recent years,
alternative donor transplantation (umbilical cord blood or
haploidentical marrow) has become more widespread, with
recent studies reporting outcomes that compare favorably to
those using matched unrelated donors [82,83]. The hap-
loidentical approach, with post-transplantation cyclophos-
phamide, has been successfully applied to patients with
lymphoma up to age 75, with a reported 1-year NRM of
10% to 15% across all age groups from 50 to 75 years, and a 3-
year survival of approximately 50% [82,84].With the growing
use and success of alternative donor transplantation, it is
expected that an even larger number of older patients will be
allo-HCT candidates, because in many cases such patients do
not have a matched sibling in sufﬁciently good health to
serve as a donor.
Based on the foregoing data, it is becoming increasingly
clear that allo-HCT is in fact feasible in older patients. Thus,
transplantation clinicians will be increasingly challenged to
consider allo-HCT for these older patients. On an individual
patient level, the decision to proceed to transplantation re-
quires a careful consideration of patient issues (comorbid-
ities, performance status), disease factors (histology and
biological features of the lymphoma, clinical aggressiveness,
disease burden), donor factors, and psychosocial factors.
These considerations are of particular importance in older
patients, in whom the therapeutic window for transplant
may be narrow and the risk for toxicity and disability post-
transplantation may be higher. With this in mind, it will be
very important to prospectively collect quality of life data in
elderly patients undergoing allo-HCT for NHL, if allo-HCT
becomes a covered indication in these patients.SUMMARY AND CONCLUSIONS
Ideally, there would be more prospective randomized
clinical trial data available to prove superior survival with
allo-HCT for FL, DLBCL, and MCL compared with alternative
approaches. No such studies have been successfully
completed to date, however. One such study was attempted
in FL, but was not completed because of poor accrual [85].
Although it is true that a number of exciting targeted, bio-
logical, and immunological therapies are emerging in NHL,
how these new therapies might enhance or replace allo-HCT
is unclear. High-quality studies comparing novel agents with
allo-HCT, or integrating such agents with allo-HCT, are
needed to answer such questions. In the meantime, based on
the extensive literature currently available and summarized
in this review, it is clear that for many patients with NHL,
allo-HCT is the sole currently available therapy that offers
cure.
Advances in the HCT ﬁeld have enabled the successful
application of this therapy in patients age >65 years. Access
to allo-HCT in the United States historically has been quite
limited owing to a lack of insurance coverage. Despite this
limiation, there is now a body of evidence showing that pa-
tients with lymphoma in their 60s and 70s can in fact tolerate
and beneﬁt from allo-HCT. Based on this evidence, we
strongly assert that allo-HCT now represents a standard of
care for older patients with NHL, and thus the associated
costs should be covered by insurance carriers.ACKNOWLEDGMENTS
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